Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CETP | P11597 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.35 |
| ▸ | TUBB | P07437 | 1/20 | 0.35 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.35 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.35 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.35 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.35 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.35 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.35 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.35 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.35 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.35 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.35 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15998764 | 0.85 | GPR84 (0.37) | CYP1A2CYP2A6ALDH1A1KDM4E | |
| SCHEMBL28211609 | 0.84 | ADORA2A (0.34) | CYP1A2CYP2A6ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL31722992 | 0.84 | ADORA2A (0.39) | CYP1A2ALDH1A1KDM4EHSD17B10TUBB4A | |
| SCHEMBL6937631 | 0.83 | GPR84 (0.45) | CYP1A2ALDH1A1KDM4EHSD17B10TUBB4A | |
| SCHEMBL1408383 | 0.82 | TUBB4A (0.45) | CYP1A2CYP2A6LMNAALDH1A1KDM4E | |
| SCHEMBL26794038 | 0.82 | PTGDR2 (0.37) | LMNACETPALDH1A1KDM4EHSD17B10 | |
| SCHEMBL30064889 | 0.82 | TUBB4A (0.45) | CYP1A2CYP2A6LMNAALDH1A1KDM4E | |
| SCHEMBL30064989 | 0.82 | NQO2 (0.43) | CYP1A2ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL15998741 | 0.82 | HTT (0.39) | LMNAALDH1A1KDM4EHSD17B10HTR6 | |
| SCHEMBL2656359 | 0.82 | NQO2 (0.43) | CYP1A2ALDH1A1KDM4EHSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230339910-A1 | RAS INHIBITORS AND METHODS OF USING THE SAME | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-10-26 | — | — | US | disclosed |
| US-20230279025-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-09-07 | — | — | US | disclosed |
| US-11548888-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-4087573-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| EP-3908283-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-11-17 | — | — | EP | disclosed |
| US-20200331911-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2020-10-22 | — | — | US | disclosed |
| WO-2020146613-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-07-16 | — | — | WO | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279025-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | CYP1A2 4527/4885CYP2A6 3249/4885LMNA 4065/4885 |
| US-11548888-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | CYP1A2 4667/4885CYP2A6 3834/4885LMNA 2991/4885 |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | CYP1A2 4576/4885CYP2A6 3523/4885LMNA 4027/4885 |
| US-20200331911-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CYP1A2 4667/4885CYP2A6 3834/4885LMNA 2991/4885 |
| US-20230339910-A1 | RAS INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | CYP1A2 4745/4885CYP2A6 4497/4885LMNA 3604/4885 |
| US-20180072723-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CYP1A2 4667/4885CYP2A6 3834/4885LMNA 2991/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | CYP1A2 4667/4885CYP2A6 3834/4885LMNA 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.